Neuronetics, Inc. (STIM)
STIMNASDAQ-GMMedical/Dental Instruments
$2.11
-0.0700 (-3.21%) today
Regular session, Nov 10, 12:26 PM ET
- Market cap
- $164.01m
- P/E
- –
- EPS, last 4 quarters
- $-0.3300
- Dividend yield
- –
- Day range
- $2.00 to $2.22
- 52-week range
- $0.8000 to $3.44
- Average volume
- 1.18m
- Previous close
- $2.18
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $6.00, +184.4% from here
Earnings
next estimate $-0.0800Next report
Dec 2025
+16.7%
Mar 2026
+5.9%
Jun 2026
+54.5%
Sep 2026
+75.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $41.78m | $34.45m | $41.57m | $41.96m |
| Gross profit | $21.70m | $16.15m | $21.22m | $21.89m |
| Operating income | -$5.04m | -$8.99m | -$1.50m | $541.0k |
| Net income | -$7.16m | -$10.79m | -$3.44m | -$1.69m |
Last four quarters: revenue $159.76m, margin -14.4%, free cash flow -$9.58m
News
8 latest- Neuronetics Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Neuronetics, Inc. Reports Third Quarter 2026 Financial and Operating ResultsFintel · 6 days ago
- Healthcare Stocks Rally: LYEL Leads With 44% Gain; LIVN, UFPT And STIM Advance On Key Updates RTTNews · 6 days ago
- Neuronetics (STIM) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Neuronetics Q3 Net Loss Narrows To $1.7 Mln As Revenue Rises 12.5%; Stock Up RTTNews · 6 days ago
- Neuronetics (STIM) Reports Q3 Loss, Tops Revenue EstimatesZacks · 6 days ago
- Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue EstimatesZacks · Oct 27, 2026
- Integra LifeSciences (IART) Surpasses Q3 Earnings EstimatesZacks · Oct 21, 2026
The company
is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- neurostar.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.